Dasatinib (Stardas) belongs to the first generation of targeted drugs

Dasatinib (Dasatinib) is a second-generation targeted drug. Targeted drugs are usually divided into several generations based on their development history and mechanism of action to better describe their characteristics and development trends.

The first generation of targeted drugs are mainly designed for a single molecular target, such as kinase inhibitors such as imatinib (Imatinib) for the treatment of chronic myelogenous leukemia. However, some cancer patients may develop drug resistance after long-term use, so second-generation targeted drugs have emerged to address this challenge.

As a second-generation targeted drug, dasatinib (Startase) has a broader spectrum of action and stronger anti-tumor activity than the first-generation drug. It can not only inhibit the kinase activity of the BCR-ABL fusion gene product, but also simultaneously affect other related signaling pathways, such as the SRC family of kinases, thereby having higher efficacy in the treatment of chronic myelogenous leukemia and other related leukemias.

Compared with first-generation drugs, second-generation targeted drugs usually have stronger anti-tumor activity, broader target effects, and less drug resistance. However, they may also bring more side effects and safety issues, so the patient's response needs to be closely monitored when used and the treatment plan adjusted according to the situation.

In general, Dasatinib (Startase) as a second-generation targeted drug, has important clinical significance in the treatment of leukemia and other malignant tumors. With the continuous development and advancement of targeted drugs, it is believed that more and more effective drugs will be available to bring better treatment effects and quality of life to cancer patients.